Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

ClinicalTrials.gov ID: NCT00086125

Public ClinicalTrials.gov record NCT00086125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies

Study identification

NCT ID: NCT00086125
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Enrollment: 57 participants

Conditions and interventions

Conditions

Interventions

ridaforolimus Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2004
Primary completion: May 31, 2006
Completion: May 31, 2006
Last update posted: Aug 18, 2015

2004 – 2006

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of Chicago Hospitals, Section of Hematology/Oncology	Chicago	Illinois	60637	—
Washington University School of Medicine, Siteman Cancer Center, 4921 Parkview Place	St Louis	Missouri	63110	—
The Cancer Institute of New Jersey	New Brunswick	New Jersey	08903	—
New York Presbyterian Hospital, Weill College of Cornell University	New York	New York	10021	—
Morris Cancer Center - Duke University Medical Center, Adult Bone Marrow Transplant Clinic	Durham	North Carolina	27705	—
Gabrail Cancer Center	Canton	Ohio	44718	—
Jeane's Hospital of TUHS	Philadelphia	Pennsylvania	19111	—
MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00086125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 18, 2015 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00086125 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →